UNC-Chapel Hill research, led by Emily Ciccone, MD, MHS, instructor and fellow in the division of infectious diseases, and Allison Aiello, PhD, professor of epidemiology and Carolina Population Center Fellow, shows that individuals previously infected with SARS-CoV-2 develop a significant antibody response to the first dose of mRNA-based COVID-19 vaccines.
New research from UNC-Chapel Hill suggests that those who have previously experienced a SARS-CoV-2 infection develop a significant antibody response to the first dose of mRNA-based COVID-19 vaccine. In fact, one dose of the vaccine could give the same level of antibody protection to those who have had COVID-19 as two doses of vaccine provide to those who have not had COVID-19.
This is welcome news for many who have recovered from the virus and are now wondering whether they should receive a vaccine when they are eligible. Previous CDC guidance indicated that those with a history of SARS-CoV-2 infection may choose to temporarily delay vaccination while supplies are limited.
Read the full article in the UNC Health and UNC School of Medicine Newsroom.
These findings were also published by ExBulletin.com.